《大行報告》花旗上調華潤醫療(01515.HK)目標價至6.9元 評級「中性」
花旗發表研究報告指,華潤醫療(01515.HK)去年度收入在醫院併購下,按年增長30%,但受疫情影響日常經營,令純利按年下跌21%。
由於需要整合新收購的醫院,華潤醫療去年度毛利率按年下跌12.9個百分點,經營溢利率下跌13.1個百分點,淨利潤率更跌7.2個百分點至11.3%。
該行表示,考慮到去年度經營溢利率遜預期,將2021至2023年每股盈利預測下調17%至20%,維持「中性」評級,預期今年業務將持續復甦,憧憬新收購的醫院整合後收入可提升,將目標價由5.6元上調至6.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.